Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 14 February, 2020

JPMorgan Asset Mngt

AbbVie Inc. 8.3 amendment

RNS Number : 0860D
JPMorgan Asset Management
14 February 2020
 

Ap19

 

 

Amendment

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Company dealt in

AbbVie Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.01 common stock

Date of dealing

12 February 2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)


Long

Short


Number


(%)

Number


(%)

(1) Relevant securities

18,808,964*               1.27*

3,126               0.00

(2) Derivatives (other than options)

1,309                           0.00

 288,072           0.02

(3) Options and agreements to purchase/sell



Total

18,810,273*               1.27*

291,198               0.02

 

*In addition to the dealings in section 2a, there is an increase in the holding of 27 common stock due to a transfer.

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short


Number


(%)

Number


(%)

(1) Relevant securities



 

(2) Derivatives (other than options)



 

(3) Options and agreements to purchase/sell



Total




Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

225

70

2,215

60

127,726

22,400

810

1,123

467,908

8,000

8

65

 

8,967

43

1,250

17

136

6,300

3,157

96.3900 USD

96.4374 USD

96.4375 USD

96.4377 USD

96.4632 USD

96.9750 USD

96.9900 USD

97.1009 USD

97.1914 USD

97.2010 USD

97.2013 USD

97.7900 USD

 

96.3014 USD

96.5300 USD

96.6172 USD

96.8000 USD

97.0274 USD

97.0491 USD

97.7900 USD

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)





 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)




 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)




Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

14 February 2020

Contact name

Daniel Swart

Telephone number

0207 134 6168

If a connected EFM, name of offeree/offeror with which connected

Allergan plc

If a connected EFM, state nature of connection (Note 10)

Financial Advisor to Allergan plc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFELFSISLII

a d v e r t i s e m e n t